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Abstract 
Development of lanthanide detoxification agents and protocols is of great 
importance in management of overdoses. Due to safety of maltol as a 
detoxifying agent in metal overloads, it can be used as a lanthanide detoxifying 
agent. In order to demonstrate the biodistribution of final complex, [
153Sm]-
samarium maltolate was prepared using Sm-153 chloride (radiochemical purity 
>99.9%; ITLC and specific activity). The stability of the labeled compound was 
determined in the final solution up to 24h as well as the partition coefficient. 
Biodistribution studies of Sm-153 chloride, [
153Sm]-samarium maltolate were 
carried out in wild-type rats comparing the critical organ uptakes. Comparative 
study for Sm
3+ cation and the labeled compound was conducted up to 48 h, 
demonstrating a more rapid wash out for the labeled compound. The effective 
and biological half lives of 2.3 h and 2.46h were calculated for the complex. The 
data suggest the detoxification property of maltol formulation for lanthanide 
overdoses. 
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Introduction 
Lanthanides have been used extensively in industry, ophthalmic and camera lenses, 
petroleum cracking, nuclear reactors, television tubes, and mirrors, to mention a few 
applications. Symptoms of acute samarium (and other lanthanides) intoxication include 
defecation, writhing, ataxia, sedation, and labored respiration, which can happen in 
accidents in reactors and other related industries. 
However, not much data are available on the lanthanide detoxification processes of the 
subjects after acute exposures. Developing lanthanide mobilization protocols using non-
toxic and human approved chelators is an interesting field in human health. 
Maltol (3-hydroxy-2-methyl-4-pyrone), a common product formed upon heating of 
carbohydrates, is an approved food additive, used to impart a desirable malty taste and 
odor to breads, cakes, beer and other beverages (Figure 1). Maltol loses its hydroxyl 
proton at neutral to basic pH levels, forming the maltolate anion; this anionic molecule 
forms a strong bidentate/tridentate chelate with gallium, iron, zinc, aluminum, vanadium [1] 
and lanthanides [2]. 
O
O
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Fig. 1.   Chemical structure of maltol 
Some of maltolate metal complexes are reported as biologically active compounds 
including gallium-maltolate for lymphoma treatment [3]. On the other hand aluminum-
maltolate complex has also demonstrated in vitro apoptotic cell death pathway in man [4] 
as well as anti-microbial effects [5].  
Maltol and its derivatives have been used in treatment of iron overload disorders such as 
haemochromatosis and thalassemia major [6] and aluminium toxication [7]. 
Due to lanthanide maltol complexes stability reports [8] and the possible application of 
maltol as a detoxifying agent in lanthanide over-exposure, in this work, we were interested 
in biodistribution and effective half life determination of a final lanthanide-maltol complex, 
i.e. [
153Sm]-samarium maltolate, as a final detoxification product in biological systems. 
Samarium was chosen as the appropriate lanthanide due to considerations, for instance, 
153Sm (T1/2 = 46.7 h) is usually prepared by neutron activation of natural and/or enriched 
152Sm2O3 [9] and is an excellent lanthanide radionuclide for biological studies due to high 
production yields in research reactors, medium energy beta particles and the existence of 
photopeak at 103 keV for detection [10]. 
Thus, in this work, the preparation, stability tests, partition coefficient determination and 
comparative biodistribution studies of [
153Sm]-samarium maltolate as the final product of 
lanthanide detoxification have been reported. 
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Results and discussion 
Production and quality control of 
153Sm 
The radionuclide was prepared in a research reactor according to regular methods with a 
range of specific activity 22–28 GBq/mg for radiolabeling use, after counting the samples 
on an HPGe detector for 5 hours, a negligible amount of impurities were recorded and 
shown to be Eu radionuclides. 
The 
153Sm radionuclide in specific activity of 28 GBq/mg was prepared for radiolabeling. 
The radioisotope diluted and evaporated to obtain the desired pH and volume was 
followed by sterile filtering. Radiochemical impurities in the 
153Sm sample used in the 
radiolabeling step were checked by two solvent systems: A, a mixture of 10 mmol/L DTPA 
solution as mobile phase on Whantman No.2 paper (pH=3), the free samarium cation in 
153Sm
3+ form, was chelated with the polydentate eluting leading to the migration of the 
cation in 
153Sm-DTPA form to higher Rf (retention factor), any other ionic species would 
lead to the observation of new radiopeaks, especially in origin. B, a mixture of 10% 
ammonium acetate:methanol (1:1) was used as another solvent system on the Whatman 
No. 2 paper, 
153Sm
3+ remains at the origin using this system while other ionic species 
would migrate to higher Rfs (Table 1). 
Tab. 1.   Chromatographic properties of [
153Sm]-samarium chloride and [
153Sm]-
samarium maltolate 
Chromatographic systems  Rf for [
153Sm]-
samarium chloride 
Rf for [
153Sm]-
samarium maltolate 
DTPA solution (pH. 5), 
Whatman no. 2  0.8 0.05 
10% ammonium 
acetate:methanol, Si  0.01 0.3 
ammonia: water: methanol 
(2:40:20), Whatman no. 2  0.05 0.8 
 
On the other hand, 10% ammonium acetate: methanol mixture was also used for the 
determination of radiochemical purity. In this solvent system, the fast eluting species were 
possibly Sm-153 cation, other than Sm
3+ (2%) and the remaining fraction at Rf.0 was a 
possible mixture of Sm
3+ and/or colloids. The difference in values of impurity in two solvent 
systems is possibly due to the presence of colloidal impurity in the sample (2%) 
(Tables 1, 2).  
Preparation of 
153Sm-MAL 
In order to obtain the highest specific activity in the shortest possible time, a quantitative 
study was designed using different amounts of MAL and various time intervals for a 
specific amount of radioactivity while 60°C was considered a suitable temperature. A 
satisfactory labeling yield of 99–100% was obtained at this temperature using 20–30 mg of 
MAL within 2 h. 268 Z.  Naseri  et al.:  
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Because of relative lipophilic [
153Sm]-samarium maltolate complex and participation of 
several polar functional groups in its structure, [
153Sm]-samarium maltolate migrated to the 
solvent frontline in ITLC while 
153Sm cation was retained in origin (Table 1). The labeling 
step took about 2 h. In all radiolabeling procedures (n=5), the labeling yield was over 99% 
(Table 2). 
Tab. 2.   Purities for radioactive samples used in this study (n=5) 
Purity (%)  [
153Sm]-samarium 
chloride 
[
153Sm]-samarium  
maltolate 
Radiochemical   98±0.2  >99 
Chemical   >99  >99 
Radionuclidic >99.9  >99.9 
 
The partition coefficient for the labeled compound was calculated (logP. 1.869) 
demonstrating a rather lipophilic complex as it could be observed from the 
chromatographic behavior. 
The final radiolabeled complex diluted in normal saline was then passed through a 0.22 
µm (Millipore) filter for sterilization. Incubation of [
153Sm]-samarium maltolate in freshly 
prepared human serum for 24 h at 37°C showed no loss of 
153Sm from the complex.  
Biodistribution studies for 
153Sm cation in wild-type rats 
The animals were killed by CO2 asphyxiation at selected times after injection (2, 4, 24 and 
48h). Dissection began by drawing blood from the aorta followed by removing the heart, 
spleen, muscle, bone, kidneys, liver, intestine, stomach, lungs and skin samples. The 
tissue uptakes were calculated as the percent of area under the curve of the related photo 
peak per gram of tissue (% ID/g) (Table 3).  
The liver uptake of the cation is comparable with many other radio-lanthanides mimicking 
calcium cation accumulation; about %3 of the activity accumulates in the liver after 48 h. 
The transferin-metal complex uptake and the final liver delivery seems the possible route 
of accumulation.  
The blood content is low at all time intervals and this shows the rapid removal of activity in 
the circulation. The lung, muscle and also skin do not demonstrate significant uptake 
which is in accordance with other cations accumulation. A %4 bone uptake is observed for 
the cation which remains almost constant after 96 h (data not shown). The spleen also has 
a significant uptake possibly related to reticuloendothelial uptake. The kidney plays an 
important role in 
153Sm cation excretion especially after 24 h. 
The accumulation of [
153Sm]-samarium maltolate is demonstrated in Table 4. The spleen, 
liver and kidney were the major accumulation sites of the radiolabeled compound.  
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Tab. 3.   Percentage of injected dose per gram (ID/g %) of 
153SmCl3 in wild-type rat 
tissues at 2, 4, 24 and 72 h post injection 
Injected dose per gram (ID/g %±SD) [
153Sm]-samarium chloride  Organs 
2h  4 h  24 h  48h 
blood 0.07±0.0676  0.0980±0.006 0.1493±0.0096 0.1302±0.09 
heart 0.26±0.0068  0.2404±0.0361 0.1495±0.0114 0.0778±0.011 
liver 4.23±0.21  4.1033±0.0686 3.1496±0.0888  3.1192±0.09 
kidney 1.3±0.117  1.2594±0.0856 1.3806±0.0404  1.2674±0.06 
skin 0.04±0.02  0.0656±0.0168 0.0503±0.0101  0.0525±0.01 
muscle 0.02±0.01  0.0218±0.0057 0.0132±0.0026  0.0109±0.02 
bone 1.16±0.015  1.1450±0.0740  1.1231±0.0581 0.8606±0.06 
intestine 0.1±0.01  0.0980±0.0205 0.0789±0.0245  0.0750±0.03 
lung 0.23±0.04  0.2157±0.0162 0.1553±0.0697  0.1006±0.05 
spleen 0.65±0.05  0.6084±0.0200 0.4629±0.0788  0.2179±0.04 
brain 0.004±0.001  0.0090±0.0011 0.0374±0.0023 0.0137±0.002 
stomach 0.18±0.09  0.1978±0.0064 0.0669±0.0045 0.1620±0.003 
 
Tab. 4.   Percentage of injected dose per gram (ID/g %±SD) of [
153Sm]-samarium 
maltolate in wild-type rat tissues at 2, 4, 24 and 72h post injection 
Injected dose per gram (ID/g %±SD) [
153Sm]-samarium 
maltolate 
Organs 
2h 4h  24h  48h 
Blood 1.0969±0.5547  0.8861±0.0106 0.1543±0.0105  0.0607±0.0060
Heart 0.6494±0.0320  0.0694±0.0027 0.1351±0.0028  0.2426±0.0269
Lung 0.5423±0.0253  0.5717±0.0100  0.2018±0.0140 0.0980±0.0064
Stomach 0.0874±0.0013  0.1846±0.002 0.0754±0.0013  0.0175±0.0013
Colon 0.0335±0.0020  0.1152±0.005 0.0273±0.002  0.0249±0.0025
Intestine 0.1446±0.0050  0.1599±0.002 0.0517±0.0041  0.0042±0.0003
Liver 4.6164±0.1846  6.1051±0.10004 3.2293±0.0779 0.8590±0.0350
Spleen 1.0166±0.0033  1.3231±0.0085 1.5545±0.0744 0.1482±0.003 
Kidney 0.8232±0.0139  0.7729±0.01405 0.7591±0.0060 0.5676±0.045 
Muscle 0.0753±0.0023  0.0261±0.002 0.0842±0.0013  0.0446±0.0017
Sternum 0.1938±0.0102  0.2968±0.01074 0.1601±0.002 0.6909±0.0204
Thigh bone  0.4438±0.0255  0.5590±0.04013 0.7005±0.007 0.0896±0.0010
Skin 0.0390±0.0015  0.0473±0.01085 0.0491±0.0103 0.1494±0.0061
Brain 0±0.00  0±0.00 0±0.00  0±0.00 
 
Regarding the blood activity content, the Sm cation content is almost intact in 48 hours 
which can be a result of metal-serum protein interactions, while in case of [
153Sm]-
samarium maltolate, the activity is rapidly decreased in 24 hours and reaches its minimum 
in 48 hours (Table 4). This is a significant detoxifying property for maltol in the presence of 
radiolanthanides. 
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Fig. 2.   Comparative %ID/g in the blood for [
153Sm]-samarium maltolate (labeled, red) 
and 
153SmCl3 (free, blue) in wild-type rats 
 
Regarding the kidney activity content, both species are excreted from the kidneys; the 
excretion difference is not significant (Figure 3). 
 
 
Fig. 3.   Comparative %ID/g in the kidney for [
153Sm]-samarium maltolate (labeled, red) 
and 
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Fig. 4.   Comparative %ID/g in the thigh bone tissue for [
153Sm]-samarium maltolate 
(labeled, red) and 
153SmCl3 (free, blue) in wild-type rats 
The bone activity content, is always a major problem in lanthanide overdose. The Sm 
cation content is almost higher at all time intervals compared with the labeled compound 
and in 48 hours almost no activity (less than 0.4%) can be observed in the bones (Fig. 4).  
 
Fig. 5.   Comparative %ID/g in the liver for [
153Sm]-samarium maltolate (labeled, red) 
and 
153SmCl3 (free, blue) in wild-type rats 
The liver activity content is another major problem in lanthanide overdoses. The Sm cation 
content is almost less in the first few hours while after 24 h it is constant at around %3. 
The whole liver activity decreases to less than %2 in 48 hours which is a satisfactory 
activity reduction for detoxification process (Figure 5). 
Considering the whole-body activity content, an accumulative activity was calculated for 
the [
153Sm]-samarium maltolate among the tissues in 4-48 time period. A polynominal 
curve can be fitted to the time-activity data with high R-square value (R
2=1). Considering 
the half activity of the starting time interval (4h, 11.1178 %ID/g), a biological half-life for the 272 Z.  Naseri  et al.:  
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complex can be determined by dissolving the equation (at x=5.55). Thus the effective half 
life of about 2.3 h is calculated for the complex. While the biological half life can be 
calculated (T1/2 biol. 2.46). 
 
Fig. 6.   Whole-body activity content/time curve for [
153Sm]-samarium maltolate in 4–48 
time period in wild-type rats 
Experimental 
Production of 
153Sm was set up at Tehran Research Reactor (TRR) using 
152Sm (n,  γ) 
153Sm reaction with 
152Sm in purity of 98.7% (ISOTEC Inc.). Maltol was purchased from 
Aldrich Co., Germany, without further purification. Chromatography paper (Whatman 
No.  2) was obtained from Whatman (Maidstone, UK). Radio-chromatography was 
performed using a bioscan AR-2000 radio TLC scanner instrument (Bioscan, Paris, 
France). A high purity germanium (HPGe) detector coupled with a Canberra™ (model 
GC1020-7500SL) multichannel analyzer and a dose calibrator ISOMED 1010 (Dresden, 
Germany) were used for counting distributed activity in rat organs. All other chemical 
reagents were purchased from Merck (Darmstadt, Germany). Calculations were based on 
the 103 keV peak for 
153Sm. All values were expressed as mean ± standard deviation 
(Mean ± SD) and the data were compared using Student’s T-test. Statistical significance 
was defined as P<0.05. Animal studies were carried out in accordance with the United 
Kingdom Biological Council's Guidelines on the Use of Living Animals in Scientific 
Investigations, 2nd ed. Male healthy rats were purchased from Pasteur Institute, Tehran, 
Iran. 
Production and quality control of 
153SmCl3 solution 
The 
153Sm was produced by neutron irradiation of 100 µg of enriched 
152Sm2O3 according 
to reported procedures [11] at a thermal neutron flux of 5×10
13 n.cm
-2.s
−1 for 5 days. 
Specific activity of the 
153Sm was 27.75 GBq/mg. The irradiated target was dissolved in 
200 µl of 1.0 mol/L HCl, to prepare 
153SmCl3 and diluted to the appropriate volume with 
ultra pure water, to produce a stock solution. The mixture was filtered through a 0.22 µm 
biological filter and sent for use in the radiolableing step. Radionuclidic purity of the 
solution was tested for the presence of other radionuclides using beta spectroscopy and   Preparation and Quality Control of the [
153Sm]-Samarium Maltolate Complex as a Lanthanide …  273 
Sci Pharm. 2011; 79: 265–275 
HPGe spectroscopy to detect various interfering beta and gamma emitting radionuclides. 
The radiochemical purity was also checked by Whatman No.2 chromatography paper, and 
developed in a mixture of 10 mmol/L DTPA solution as a mobile phase. 
Labeling maltolate with 
153SmCl3 
The labeling was developed in ethanolic media. Briefly, 
153SmCl3 (111 MBq, 0.1 ml) was 
added to a borosilicate vial and dried by warming (50°C) under a nitrogen flow for about 15 
minutes. Then, maltol (30mg, 0.25 mmol) dissolved in absolute ethanol (1 ml) was added 
to the dried residue and the mixture agitated and incubated at 60°C for 2 hours. The 
radiochemical purity of free samarium and Sm-MAL were determined by counting 
Whatman No.2 sheets as stationary phase using various mobile phases (A: 
ammonia:water:methanol (2:40:20), B: 1mM DTPA aqueous solution, C: %10 ammonium 
acetate:methanol system, 1:1). After obtaining the desired radiochemical purity, the 
ethanolic solution was concentrated by warming 40–50°C to 0.05 ml and then diluted to a 
5% solution by adding 1 ml of normal saline. 
Stability testing of the radiolabeled compound in aqueous solution 
Stability of [
153Sm]-samarium maltolate in final preparation was determined by storing the 
final solution at 25°C for 24 h and performing frequent ITLC analysis using 
ammonia:water:methanol (2:40:20) mobile phase to determine radiochemical purity.  
Stability of [
153Sm]-samarium maltolate in presence of human serum 
Final [
153Sm]-samarium maltolate solution (7.5 MBq, 50 µl) was incubated in the presence 
of freshly prepared human serum (300 µl) and kept at 37°C for 2 days. The complex 
stability was assessed by performing frequent ITLC analysis using 
ammonia:water:methanol (2:40:20) mobile phase to determine radiochemical purity.  
Determination of Partition coefficient 
The partition coefficient of the [
153Sm]-samarium maltolate was measured following 1 min 
of vigorous vortex mixing of 1 ml of 1-octanol and 1 ml of isotonic acetate-buffered saline 
(pH=7) with approximately 3.7 MBq of the radiolabeled complex at 37°C. Following further 
incubation for 5 min, the octanol and aqueous phases were sampled and counted in an 
automatic well counter. A 500 µl sample of the octanol phase from this partitioning was 
repartitioned two to three times with fresh buffer to ensure that traces of hydrophilic 
153Sm 
impurities did not alter the calculated P values. The reported log P values are the average 
of the second and third extractions from three to four independent measurements, log P 
values represent the mean (standard deviation) of five measurements. 
Biodistribution of [
153Sm]-samarium maltolate and 
153SmCl3 in normal rats 
To determine comparative biodistribution, [
153Sm]-samarium maltolate and 
153SmCl3 were 
administered to normal rats in separate groups (n=3). A volume (100–120 μl) of final 
[
153Sm]-samarium maltolate solution (4800±185 KBq) radioactivity was injected intra-
venously to rats through their tail vein. The animals were sacrificed at the exact time 
intervals (2, 4, 24 hours and 48 h), and specific activity of different organs was calculated 
as percentage of injected dose per gram using HPGe detector. 274 Z.  Naseri  et al.:  
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Conclusion 
In this work, [
153Sm]-samarium maltolate was prepared using Sm-153 chloride 
(radiochemical purity >99.9%; ITLC and specific activity). The stability of the labeled 
compound was determined in the final solution up to 24h as well as the partition 
coefficient. The partition coefficient for the labeled compound was calculated (logP. 1.869). 
Biodistribution studies of Sm-153 chloride and [
153Sm]-samarium maltolate were carried 
out in wild-type rats comparing the critical organ uptakes. Comparative studies for Sm
3+ 
cation and the labeled compound were conducted up to 48 h, demonstrating a more rapid 
wash out of activity for the labeled compound. The effective half life of about 2.3 h was 
calculated for the complex and the biological half life was 2.46 h. The radioactivity in case 
of the labeled compound is significantly removed from the blood and bone. The data 
suggests the detoxification property of maltol formulation for lanthanide overdoses. 
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